VIVUS (VVUS) Sinks on Conference Call; 30% of Qsymia Scipts Abandoned Due to Cash Outlay
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Price: $0.47 --0%
Financial Fact:
Loss from operations: -848K
Today's EPS Names:
ESCA, LICT, NKSH, More
Financial Fact:
Loss from operations: -848K
Today's EPS Names:
ESCA, LICT, NKSH, More
Join SI Premium – FREE
VIVUS (Nasdaq: VVUS) continues to sink following comments on its quarterly conference call Tuesday morning.
The following are a few key pieces from VIVUS conference call:
VIVUS is now down 10 percent, after being up 4 percent or so immediately following third-quarter results. For more, click here.
The following are a few key pieces from VIVUS conference call:
- 3,504 patients are on Qsymia to date;
- Average price for 1-month supply is $160, with 20 percent reimbursement coverage since launch; and
- About 30 percent of Qsymia prescriptions are abandoned due to cash outlay.
VIVUS is now down 10 percent, after being up 4 percent or so immediately following third-quarter results. For more, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BayCom Corp (BCML) Misses Q1 EPS by 4c
- EverQuote to Announce First Quarter 2024 Financial Results on May 6, 2024
- Marten Transport (MRTN) Misses Q1 EPS by 2c
Create E-mail Alert Related Categories
Conference CallsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
